Quintiles Introduces Continuous Glucose Monitoring Services to Improve Diabetes Outcomes
June 24 2016 - 6:45AM
Business Wire
Quintiles today announced the launch of its new Continuous
Glucose Monitoring (CGM) service offering. This new solution
combines innovative, wearable technology with Quintiles’ deep
therapeutic and analytical expertise to help enhance the efficiency
and quality of diabetes-focused clinical trials.
When used in clinical research, the new CGM offering will
provide investigators with access to a myriad of customized data
analytics and performance reports through its award-winning
Quintiles Infosario® technology platform. These optimized glycemic
data sets can be analyzed more efficiently to uncover trends such
as non-compliance and potential safety triggers faster than
traditional diabetes monitoring models. In addition, Quintiles
experts from the company’s Diabetes Center of Excellence will
provide dedicated support for the offering – combining data and
therapeutic expertise to drive smarter protocol design and enhance
patient safety and compliance.
“According to the International Diabetes Federation (IDF), every
six seconds, a person dies from diabetes-related causes and almost
half of those deaths are people under the age of 60,” said Margaret
Keegan, president of Data Sciences, Safety and Regulatory Services
at Quintiles. “With diabetes diagnoses on the rise, the need for
innovative and accessible treatments also increases. CGM can
provide a variety of in-depth measures from diabetes patients –
information that can be used to enhance the way patients are
treated for diabetes and why this new offering is so critical.”
Through the offering, continuous glucose measurements will be
captured by a wearable sensor and wirelessly sent to a receiver,
recording readings throughout the day. In the clinical trial
setting, this comprehensive and timely glucose visibility has the
potential to improve patient safety, accelerate clinical
development and provide a basis for differentiated claims.
“We are excited to bring this new CGM offering to the market as
a complement to Quintiles’ technology integration strategy,” said
Sam Osman, head of Cardiac Safety Services at Quintiles. “We
believe this new technology solution incorporating biosensors and
wearables, which can be used across all drug development phases,
will improve the way the industry tracks and improves diabetes care
for patients worldwide.”
To learn more about Quintiles Continuous Glucose Monitoring,
visit quintiles.com/cgm.
About Quintiles
Quintiles (NYSE: Q) helps biopharma and other healthcare
companies improve their probability of success by connecting
insights from our deep scientific, therapeutic and analytics
expertise with superior delivery for better outcomes. From advisory
through operations, Quintiles is the world’s largest provider of
product development and integrated healthcare services, including
commercial and observational solutions. Conducting operations in
approximately 100 countries, Quintiles is a member of the FORTUNE
500 and has been named to FORTUNE’s list of the “World’s Most
Admired Companies.” To learn more,
visit www.quintiles.com.
Click here to subscribe to Mobile Alerts for Quintiles.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160624005049/en/
QuintilesMedia RelationsPhil BridgesOffice: +
1-919-998-1653Mobile: +
1-919-457-6347phil.bridges@quintiles.comorInvestor RelationsTodd
Kasper+1-919-998-2590InvestorRelations@quintiles.com
IQVIA (NYSE:IQV)
Historical Stock Chart
From Mar 2024 to Apr 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Apr 2023 to Apr 2024